Member Info for Porter_

Just read this and thought something similar could be going on here at Traf:

https://news.sky.com/story/challenger-bank-redwood-to-go-public-as-rowland-engineers-r8-tie-up-12974340

Good to see the big buys actually showing now instead of unknown trades. Could #DATA finally be ready to move or a multibag RNS drop?

Good to see Eric delivering on his promises.

Now we patiently await the update on the animal product, contract with the animal pharma company, patent approval and non-dilutive funding. 👏🏻

TR1’s coming in thick

Bulk buyers hoovering up shares off book.

Smells like a takeover to me!

Holding tight to my golden nuggets!

#OCTP 🧪💊🩺🧬🔬🌱

Oxford Cannabinoid Technologies

Medicinal cannabis company, developing products for areas such as irritable bowel syndrome and cancer induced pain, in a market worth $bn’s.

* Programme 1 medical trial results due imminently

* Company will be taking their findings to the FDA for further US approval

* Gearing up for new compound patent application that is believed to perform better than THC

* Already have an exclusive library of approx 14 cannabinoid patents with 500 derivatives

* Listed on both the LSE and OTC

* Main investors include Imperial Brands who own Blu vapes and Snoop Dogg through Casa Verde, who invest heavily in the cannabinoid sector

* New joiners to the company include:

- Dr Tim Corn as Chief medical officer (Ex Jazz and a cancer pain expert who has successfully developed and sold a number of listed companies); and

- Dr Paul Farquhar-Smith as External Advisor (leads the only cancer pain clinic in the UK, at the Royal Marsden, where Prince William is the President); and

- Rob Bennett as General Counsel (a firm background in high profile mergers and acquisitions).

Thanks guys. I also watched the interview that Genflow have just reposted from 2 years ago. Eric reminded me that his history involves running NASDAQ listed companies and that 2 years ago he was certain that in year 2, he would be announcing a big contract with an animal healthcare company. Let’s hope that he’s true to his word and we get that statement of intent confirming the contract agreement before the end of the year:

https://youtu.be/SNMv-PHBpv8?feature=shared

Still excited to see how the meeting with the België government went, how the patent application is going and if he’s still involved with Johnson and Johnson (Janssen Pharma) on developing more programmes through the company.

Https://podcasts.apple.com/gb/podcast/otcqb-podcast/id1193668018?i=1000626701363

Just listened to the companies latest podcast, Eric said that he’s expecting a crazy money buy out as soon as the FDA recognise ageing as a disease and he expects it soon, and that’s why he listed in both the UK and US to get the interest of the big pharma above all over companies who work in similar fields. He also said that something similar had happened to him before in another company and the warning signs are there for him once again. Holding tight!

Buyers are creeping in and the SP is certainly recovering.

Will be interesting to see what this quarters results bring.

We already know the sales for this year alone are as big, if not bigger than the current MCAP!

People are still buying, maybe they think a better offer could come along 👀

IMO the company is worth far more, as they have patented technology and their model is set around facial recognition for security access and control, with government contracts in place, which would be highly desired by the main big tech’s. Either way, I’m happy with today’s offer and hope the company are successful with the support of new management.

When OCTP IPO’d they were very clear on time frames and that the company would need a few years to get on its feet. They never sold a dream of instant multibags. However, smart investors stuck around and used the dips to increase their position. It’s interesting all these people who are not invested have suddenly popped up as share experts. Just because the hare may be faster, doesn’t stop the tortoise from winning the race. I’ll happily wait years if it means I can mega bag, as opposed to have gains of a measly 35% 👌🏻

Well said @F458

I personally have no concerns with cash flow, as companies would love to get their hands on the exclusive patented licenses for medical grade cannabinoids.

The team have been working amazingly hard to establish top tier relationships with some of the best names in the industry. No way would Dr’s Paul and Tim put their names to this company, unless they were certain if it’s brilliance.

Everything Clarissa has said the company will do has been achieved and I have confidence that all future goals will be met.

Like you said, people have to do their own research but the doubters loss will be our gain 😁

Good to see the market picking up on the work Genf are going, with a few new faces jumping in.

It’s an exciting time, as:

- The team start to do more talks on longevity around the world, attracting new investors and collaborative partners

- The patent could land any day

- We’re expecting the TR1 news that Sam is out, through her own financial concerns and nothing to do with Genf

- Also expecting news from the België government that human trials can begin

- Plus there’s the animal longevity trials. All it would take is a pet pharma or wholesalers company to partner up and the share could go crazy

- Then, although the company has a cash runway until 2025, Eric is always good at finding non dilutive funding, so we could land another grant

- Finally, the float is super low as Eric himself has snapped up much of the stock, with sticky hands holding in other areas. We’ve seen how just the smallest of volume moves the share price, definitely something that attracted me to the investment

Exciting time to jump on board considering the share is so cheap!

Over 25% share price increase the past 2 weeks in OCTP, and yet it seems to have gone under radar in the market. Such will be the case if we 4 bag on news and only the chosen few shall reep the rewards 😁

That would be amazing Bamb if we saw 4p in the near future. Let’s face it, we’ve seen some terrible shares x20 recently with no material product whatsoever, yet OCTP have patent exclusivity and the contacts to make their research a unicorn.

One of OCTP’s goals was to make programme 1 available to the NHS and patients by 2027, but bringing in Dr Paul with his own CIPN practice is a move of excellence, as imo, it pretty much guarantees that as long as administered by a registered GP, medicine can reach pre-qualified patients much sooner.

Unofficial research by other industry professionals, already gives insight into what the outcome looks set to be, we just need that stamp of validation. Put the seat belt on, so they say!

By the looks of it HELD has more investors dumping than buying and the promised first crop after coming out of suspension still hasn’t materialised. I’ll stick to buying OCTP shares as my investment goes up, not down thanks 👌🏻

Come back when you’ve got something positive to say about anything Amin 👌🏻

Zak notes target 4.1 over the next month with bullish divergence:

https://twitter.com/share_talk/status/1688505282803253249?s=46&t=E4FJrNGW12jbZf0LEA0XWg

Yep looking leaky a.f.

I refused to sell a bean despite the price action as know this share could blow at any moment.

I’ve had an order in for 2.25 for the past 15 mins and it’s not getting fulfilled. Either there’s a big buyer or they have no shares 👀